Key result
Ranolazine significantly prolongs exercise duration and time to angina, and reduces angina attacks and nitroglycerin consumption without significantly affecting heart rate and blood pressure.
Why the study?
Does ranolazine improve exercise duration and reduce angina attacks?
Does ranolazine improve exercise duration and reduce angina attacks?
Ranolazine is an effective anti-ischaemic drug that improves exercise capacity and reduces angina symptoms without significantly altering hemodynamics.
Answers are grounded in this paper and cite their sources.
Supports ranolazine for angina symptom relief without hemodynamic effects; hypothesis-generating from Level 5 review, needs prospective validation.
Ranolazine is a unique anti-ischaemic drug that does not significantly affect haemodynamic parameters such as heart rate and blood pressure. Ranolazine has been shown in clinical trials to significantly prolong exercise duration and time to angina, as monotherapy or when administered with conventional anti-anginal therapy. It also reduces angina attacks and consumption of nitroglycerin and is well tolerated at therapeutic doses.
No takes yet. Share an insight, caveat, or question.
Jean‐Pierre Bassand (2006) conducted a review in Angina. Ranolazine was evaluated. Ranolazine significantly prolongs exercise duration and time to angina, and reduces angina attacks and nitroglycerin consumption without significantly affecting heart rate and blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: